Literature DB >> 11296454

[A case of Sjögren's syndrome with dermatomyositis who died of rapidly progressive interstitial pneumonia].

A Fukumura1, N Ogawa, K Simoyama, H Karasawa, J Okada, C G Kim, H Kawabata, Y Masaki, Y Wano, S Sugai.   

Abstract

We report a case of 55 year-old woman with six year history of Sjögren's syndrome developed fatal rapidly progressive interstitial pneumonia. She had been well until February 1999. She developed swelling and erythematous lesions in the cheek and hands in spring 1999. She was admitted to our hospital for investigations of skin lesions in May 1999. Physical examination on admission revealed small hemorrhagic lesions in the nailfold. Serum CK level was slightly elevated. Electromyogram and MRI suggested mild myositis in the proximal upper extremities. She was suspected to have dermatomyositis along with Sjögren's syndrome. Prednisolone 10 mg/day had been given for her skin problems since March 1999. Suddenly, dyspnea on exertion was appeared on 34th day of admission. Chest X-ray film showed an acute worsening of interstitial pneumonia. Methylprednisolone pulse therapy (1000 mg for 3 days) and cyclophosphamide pulse therapy (500 mg for a day) were started, and she was subsequently treated with 60 mg/day of prednisolone and 250 mg/day of Cyclosporin A. However, interstitial pneumonia did not respond to the treatment, and pneumomediastinum and pneumothorax have developed. She died of respiratory failure on 55th day. We consider that most likely explanation for fatal interstitial pneumonia is concomitantly occurred dermatomyositis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296454

Source DB:  PubMed          Journal:  Ryumachi        ISSN: 0300-9157


  1 in total

1.  Association between Sjogren's syndrome and respiratory failure: put airway, interstitia, and vessels close together: a national cohort study.

Authors:  Jun-Jun Yeh; Hsuan-Ju Chen; Tsai-Chung Li; Yi-Sin Wong; Hsien-Chin Tang; Ting-Chun Yeh; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.